Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods

Alzheimers Res Ther. 2021 Apr 16;13(1):79. doi: 10.1186/s13195-021-00812-9.

Abstract

Background: CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profiles in CSF extracted using either gravity drip or aspiration.

Methods: Biomarkers for β-amyloidopathy (Aβ1-42, Aβ1-40), tauopathy (total tau), or synapse pathology (BACE1, Neurogranin Trunc-p75, α-synuclein) were assessed between gravity or aspiration extraction methods in a sub-population of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (cognitively normal, N = 36; mild cognitive impairment, N = 8; Alzheimer's disease, N = 6).

Results: High biomarker concordance between extraction methods was seen (concordance correlation > 0.85). Passing Bablock regression defined low beta coefficients indicating high scalability.

Conclusions: Levels of these commonly assessed CSF biomarkers are not influenced by extraction method. Results of this study should be incorporated into new consensus guidelines for CSF collection, storage, and analysis of biomarkers.

Keywords: Alzheimer’s disease; Amyloid beta; Biomarkers; Cerebrospinal fluid; Collection; Concordance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / diagnosis
  • Amyloid Precursor Protein Secretases
  • Amyloid beta-Peptides
  • Aspartic Acid Endopeptidases
  • Australia
  • Biomarkers
  • Cognitive Dysfunction* / diagnosis
  • Humans
  • Peptide Fragments
  • tau Proteins

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Peptide Fragments
  • tau Proteins
  • Amyloid Precursor Protein Secretases
  • Aspartic Acid Endopeptidases